Interest has been intensifying upon a chemokine intermediate, fractalkine, and its receptor present on glial-cells, which could be disrupted in ME/CFS patients, thus inducing glial-cell activation (45). Here, CX3CL1 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.